

Alicia Tosoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10917795/publications.pdf>

Version: 2024-02-01

52
papers

3,585
citations

279798

23
h-index

197818

49
g-index

53
all docs

53
docs citations

53
times ranked

4446
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?. <i>Cancers</i> , 2022, 14, 333.	3.7	6
2	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022, 82, 491-510.	10.9	18
3	Machine learning in neuro-oncology: toward novel development fields. <i>Journal of Neuro-Oncology</i> , 2022, 159, 333-346.	2.9	5
4	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021, 11, 342.	2.6	15
5	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021, 145, 171-178.	2.8	7
6	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	2.0	9
7	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , 2021, , 030089162110172.	1.1	1
8	A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in Metastatic Tumors Treated with Nivolumab: An Exploratory Study. <i>Diagnostics</i> , 2021, 11, 979.	2.6	5
9	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 457-473.	3.8	19
10	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021, 26, 865-878.	3.7	39
11	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , 2021, 10, CNS72.	3.0	54
12	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021, 13, 3750.	3.7	16
13	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021, 41, 757-773.	2.2	1
14	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	1.4	2
15	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1265-1272.	2.4	4
16	Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. <i>European Journal of Cancer</i> , 2020, 137, 10-17.	2.8	25
17	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 785-795.	2.4	23
18	Concordance between RTOG and EORTC prognostic criteria in low-grade gliomas. <i>Future Oncology</i> , 2019, 15, 2595-2601.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?. <i>Oncologist</i> , 2019, 24, 664-670.	3.7	3
20	The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power. <i>World Neurosurgery</i> , 2018, 112, e342-e347.	1.3	36
21	The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?. <i>Future Oncology</i> , 2018, 14, 1559-1567.	2.4	17
22	Temozolomide rechallenge in recurrent glioblastoma: when is it useful?. <i>Future Oncology</i> , 2018, 14, 1063-1069.	2.4	11
23	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017, 8, 55575-55581.	1.8	10
24	ACTR-01. THE ROLE OF CLINICAL CHARACTERISTICS IN LOW GRADE GLIOMAS PATIENTS IN THE ERA OF MOLECULAR BIOMARKERS: A STUDY FROM GRUPPO ITALIANO COOPERATIVO DI NEURO-ONCOLOGIA (GICNO). <i>Neuro-Oncology</i> , 2016, 18, vi1-vi1.	1.2	0
25	Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences. <i>Current Treatment Options in Oncology</i> , 2016, 17, 49.	3.0	48
26	Nitrosoureas in the Management of Malignant Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 13.	4.2	43
27	Patient outcomes following second surgery for recurrent glioblastoma. <i>Future Oncology</i> , 2016, 12, 1039-1044.	2.4	25
28	The role of clinical characteristics and molecular biomarkers in low grade gliomas (LGG): A GICNO study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2032-2032.	1.6	0
29	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. <i>Oncologist</i> , 2015, 20, 166-175.	3.7	66
30	Post progression survival in glioblastoma: where are we?. <i>Journal of Neuro-Oncology</i> , 2015, 121, 399-404.	2.9	10
31	The effect of re-operation on survival in patients with recurrent glioblastoma. <i>Anticancer Research</i> , 2015, 35, 1743-8.	1.1	42
32	Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?. <i>Neuro-Oncology Practice</i> , 2014, 1, 166-171.	1.6	23
33	Can average-risk medulloblastoma adult patients be treated with radiotherapy and plus chemotherapy?. <i>Journal of Clinical Oncology</i> , 2014, 32, 2022-2022.	1.6	0
34	A large prospective Italian population study (Project of Emilia-Romagna Region in Neuro-Oncology;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 methylation status in the elderly population.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2021-2021.	1.6	0
35	Gangliogliomas: recent advances in classification and treatment. <i>Future Neurology</i> , 2010, 5, 557-568.	0.5	2
36	O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. <i>Neuro-Oncology</i> , 2010, 12, 283-288.	1.2	110

#	ARTICLE	IF	CITATIONS
37	Treatment options for recurrent glioblastoma: pitfalls and future trends. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 613-619.	2.4	33
38	Bevacizumab in brain tumors: ready for primetime?. <i>Future Oncology</i> , 2009, 5, 1183-1184.	2.4	5
39	Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034. <i>Journal of Clinical Oncology</i> , 2009, 27, 1268-1274.	1.6	503
40	Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 165-179.	4.4	56
41	Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With <i>MGMT</i> Promoter Methylation Status. <i>Journal of Clinical Oncology</i> , 2009, 27, 1275-1279.	1.6	311
42	Glioblastoma in adults. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 139-152.	4.4	156
43	Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. <i>Clinical Cancer Research</i> , 2008, 14, 957-960.	7.0	125
44	Association between response to primary treatments and <i>MGMT</i> status in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1781-1786.	2.4	7
45	<i>MGMT</i> Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients. <i>Journal of Clinical Oncology</i> , 2008, 26, 2192-2197.	1.6	760
46	Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology. <i>Neuro-Oncology</i> , 2008, 10, 361-367.	1.2	233
47	Long-term results of a prospective study on the treatment of medulloblastoma in adults. <i>Cancer</i> , 2007, 110, 2035-2041.	4.1	126
48	Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 4746-4753.	1.6	171
49	Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). <i>Journal of Clinical Oncology</i> , 2004, 22, 4779-4786.	1.6	113
50	First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. <i>Journal of Clinical Oncology</i> , 2004, 22, 1598-1604.	1.6	97
51	The pathogenesis and treatment of brain metastases: a comprehensive review. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 52, 199-215.	4.4	130
52	Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. <i>Cancer</i> , 2004, 101, 2079-2085.	4.1	37